Ridgeback Capital News Today

NYU Langone Health received $15 million from philanthropists Wendy and Wayne Holman earlier this month, marking the largest gift ever given to the NYU Grossman School of Medicine by one of its alumni. The contribution will be put toward expanding research in endocrinology, diabetes and metabolism.  Wayne said the donation aims to enhance support for...

Plus, McKenzie Scott gave $15 million to support Lutheran Immigration and Refugee Service, and three universities and the MD Anderson Cancer Center all landed big gifts.

Crisp, founded by Are Traasdahl, is a retail data connectivity platform that provides unprecedented visbility into the supply chain

Food industry news, voices and jobs. Optimized for your mobile phone.

Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical...

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad

/PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants May 5, 2021 at 10:55 am Jesse Salk, CEO and co-founder of TwinStrand Biosciences. (TwinStrand Photo) New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total venture capital funding is now north of $70 million for the 6-year-old company. Double strands of...

Ikena Oncology and Senti Biosciences Each Raise Series B Rounds Posted on 01/07/2021 Ikena Oncology, Inc. is a clinical-stage biotechnology company that seeks to discover and develop patient-directed, biomarker-driven cancer therapies. Ikena Oncology announced the closing of US$ 120 million in a Series B financing round. The round was led and syndicated by Omega Funds and included participation from additional new investors: Fidelity Management & Research Company, LLC, Surveyor Capital (a Citad...